Hopp til hovedinnhold

ADHD- Hyperkinetiske forstyrrelser hos voksne

Sist revidert:
Sist revidert av:
Definisjon:
Nevroutviklingsforstyrrelse karakterisert av vedvarende konsentrasjonsvansker og/eller hyperaktivitet/impulsivitet som fører til nedsatt fungering i hverdagen
Forekomst:
Hyperkinetisk forstyrrelse (smalere definisjon enn ADHD) forekommer hos 2,5-4% av den voksne befolkningen
Symptomer:
Forstyrrelser av konsentrasjon, oppmerksomhetsevne, impulser og motorisk aktivitet, med funksjonsnedsettelse på minst to områder (utdanning/arbeid/sosiale relasjoner/fritid/hjemmemiljø)
Funn:
Uoppmerksomhet, rastløshet og motorisk uro
Diagnostikk:
Baseres på anamnese og status
Behandling:
Individuelt tilpasset. Bl.a. informasjon, veiledning, legemiddelbehandling, kognitiv atferdsterapi. Ved høy alvorlighetsgrad anbefales flere samtidige tiltak
  • ADHD/hyperkinetisk forstyrrelse - Nasjonal faglig retningslinje for utredning, behandling og oppfølging. Helsedirektoratet. Sist faglig oppdatert 04. mai 2022.
  1. ADHD/hyperkinetisk forstyrrelse - Nasjonal faglig retningslinje for utredning, behandling og oppfølging. Helsedirektoratet. Sist faglig oppdatert 04. mai 2022.
  2. Young JL, Goodman DW. Adult Attention-Deficit/Hyperactivity Disorder Diagnosis, Management, and Treatment in the DSM-5 Era. Prim Care Companion CNS Disord. 2016;18(6):10.4088/PCC.16r02000. Published 2016 Nov 17. PMID: 27907271 PubMed  
  3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4h ed. Washington, DC: American Psychiatric Association, 1994.
  4. Surén P, Bakken IJ, Lie KK et al. Differences across counties in the registered prevalence of autism, ADHD, epilepsy and cerebral palsy in Norway. Tidsskr Nor Legeforen 2013; 133: 1929-34. pmid:24084968 PubMed  
  5. Ørstavik R, Gustavson K, Rohrer-Baumgartner N et al. ADHD i Norge. En statusrapport. Folkehelseinstituttet, Oslo, 2016. ISSN: 1503-1403 www.fhi.no  
  6. Surén P, Bakken IJ, Aase H et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics 2012; 130(1): e152-8. pmid:22711729 PubMed  
  7. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009; 194(3): 204-11. British Journal of Psychiatry  
  8. Ginsberg Y, Quintero J, Anand E et al. Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients: A Review of the Literature. Prim Care Companion for CNS Disord. 2014;16:13r01600. PMID: 25317367 PubMed  
  9. Biederman J, Fried R, Petty CR, et al. Cognitive development in adults with attention- deficit/hyperactivity disorder: a controlled study in medication-naïve adults across the adult life cycle. J Clin Psychiatry 2011;72:11-6. PubMed  
  10. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychological Medicine. 2006;36(2):159-65. PubMed  
  11. Reseptregisteret, Folkehelseinstituttet. Søk 23.08.2019 www.reseptregisteret.no  
  12. Kooji JJS, Bijlenga D, Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry 2018; 56: 14-34. pmid:30453134 PubMed  
  13. Arnsten AF, Rubia K. Neurobiological Circuits Regulating Attention, Cognitive Control, Motivation, J Am Acad Child Adolesc Psychiatry. 2012;51(4):356-67. PMID: 22449642. PubMed  
  14. Volkow ND, Swanson JM. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med. 2013 Nov 14;369(20):1935-44. PubMed  
  15. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet 2016; 387: 1240-50. pmid:26386541 PubMed  
  16. Fevang SK, Hysing M, Markestad T, Sommerfelt K. Mental Health in Children Born Extremely Preterm Without Severe Neurodevelopmental Disabilities. Pediatrics 2016. e20153002. pmid:26944946 PubMed  
  17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.
  18. ICD-10. Den internasjonale statistiske klassifikasjonen av sykdommer og beslektede helseproblemer. Norsk versjon. Oslo : Statens Helsetilsyn, 1996. Sist revidert 01.01.2019 finnkode.ehelse.no  
  19. Psykiatriprogram om ADHD, Psykiatristöd SLL.
  20. NICE guidelines NG87 Attention deficit hyperactivity disorder: Diagnosis and management. Publisert: mars 2018. Sist oppdatert: 13.9.2019. www.nice.org.uk  
  21. Instanes JT, Klungsøyr K, Halmøy A, Fasmer OB, Haavik J. Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review. J Atten Disord. 2018 Feb;22(3):203-228. doi: 10.1177/1087054716669589. Epub 2016 Sep 1. PMID: 27664125 PubMed  
  22. Cortese S, Adamo N, Del Giovane C et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry 2018; 5: 727-738. pmid:30097390 PubMed  
  23. Huss M, Ginsberg Y, Tvedten T, et al. Metylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Adv Ther 2014; 31: 44-65. doi:10.1007/s12325-013-0085-5 DOI  
  24. Cândido RCF, Menezes de Padua CA, Golder S, Junqueira DR. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2021;1(1):CD013011. Published 2021 Jan 18. The Cochrane Library  
  25. Boesen K, Paludan-Müller AS, Gøtzsche PC, Jørgensen KJ. Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2022, Issue 2. Art. No.: CD012857. The Cochrane Library  
  26. Storebø O, Ramstad E, Krogh H, Nilausen T, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD009885. DOI: 10.1002/14651858.CD009885.pub2 DOI  
  27. Castells X, Blanco-Silvente L, Cunill R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD007813. DOI: 10.1002/14651858.CD007813.pub3 DOI  
  28. Cunili R, Castells X, Tobias A, Capella D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. Pharmacoepidemiol Drug Saf 2013; 22: 961-9. pmid:23813665 PubMed  
  29. Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD009504. DOI: 10.1002/14651858.CD009504.pub2 DOI  
  30. Young S, Amarasinghe M. Practitioner review: Non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psych 2010;51(2):116-133. PubMed  
  31. ADHD – Diagnostik och behandling, vårdens organisation och patientens delaktighet. En systematisk litteraturöversikt. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2013. SBU-rapport nr 217.
  32. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs ralaxation with educational support for medication-treated adults with ADHD and persistent symptoms. JAMA 2010; 304: 875-80. www.ncbi.nlm.nih.gov  
  33. Sonuga-Barke EJ, Brandeis D, Cortese S, et al; European ADHD Guidelines Group. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry. 2013 Mar 1;170(3):275-89. PubMed  
  34. Heilskov Rytter MJ, Andersen LB, Houmann T, Bilenberg N, Hvolby A, Mølgaard C, Michaelsen KF, Lauritzen L. Diet in the treatment of ADHD in children-A systematic review of the literature. Nord J Psychiatry 2014;16:1-18. PubMed  
  35. Franke B, Michelini G, Asherson P et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol 2018; 28: 1059-88. pmid:30195575 PubMed  
  36. Halmoy A et al. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord. 2009 Sep;13(2):175-87. PubMed  
  37. Young S, Thome J. ADHD and offenders. World J Biol Psychiatr. 2011;12 (Suppl. 1):124-8. PMID: 21906010. PubMed  
  38. Chang Z, et al. Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry. 2013 E-pub 2013 Oct 25. DOI: 10.1111/jcpp.12164. DOI  
  39. Lichtenstein P, et al. Medication for Attention Deficit–Hyperactivity Disorder and Criminality. N. Engl. J. Med. 2012;367(21):2006-2014. PubMed  
  40. Chang Z, et al. Serious Transport Accidents in Adults with Attention-Deficit/Hyperactivity Disorder and the Effect of Medication: A Population-Based Study. JAMA Psychiatry. 2014 Jan 29. PMID: 24477798. PubMed  
  41. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E; European Guidelines Group. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011 Jan;20(1):17-37. doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3. PMID: 21042924 PubMed  
  42. Berg A, Bråtane E, Odland HH. Kardiovaskulær risikovurdering ved bruk av AD/HD-medikamenter hos barn. Tidsskr Nor Legeforen 2014; 134: 710-4. doi:10.4045/tidsskr.13.0565 DOI  
  • Silje Folven Barlindhaug, spesialist i allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Ylva Ginsberg, med dr och överläkare, PRIMA Barn- och Vuxenpsykiatri AB, Stockholm